Issei Takeuchi1,2,3, Haruhiko Onaka1, Kimiko Makino1,2,3. 1. Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641, Yamazaki, Noda, Chiba 278-8510, Japan. 2. Center for Drug Delivery Research, Tokyo University of Science, 2641, Yamazaki, Noda, Chiba 278-8510, Japan. 3. Center for Physical Pharmaceutics, Tokyo University of Science, 2641, Yamazaki, Noda, Chiba 278-8510, Japan.
Abstract
BACKGROUND: Recently, polyethylene glycol (PEG) modified gold nanoparticles have been studied to maintaining long-term stability in biological fluids. Its biodistribution was also reported, however, comparison of bare gold nanoparticles and PEGylated gold nanoparticles with equal particle size is not sufficient. OBJECTIVE: We prepared bare gold nanoparticles and PEGylated gold nanoparticles with diameters of 20-30-nm or 50-nm to avoid the influence of particle diameter, and studied their biodistribution in the mouse. METHODS: Gold concentrations in brain, heart, lungs, liver, stomach, pancreas, spleen, kidneys, blood, urine, and feces were measured at 0.5, 1, 2, 3, 6, 12, 18, 24, and 48 h after administration of gold nanoparticles using inductively coupled plasma atomic emission spectrometry. RESULTS: At 48 h after intravenous administration, accumulation in the liver and spleen was significantly reduced by PEGylation, and the gold amounts of PEGylated gold nanoparticles with diameters of 20-30 nm and 50-nm in the brain were 3.6 times and 2.7 times higher than those of bare gold nanoparticles, respectively. CONCLUSIONS: These results indicated that the usefulness of PEGylated gold nanoparticles with small particle size for a drug carrier.
BACKGROUND: Recently, polyethylene glycol (PEG) modified gold nanoparticles have been studied to maintaining long-term stability in biological fluids. Its biodistribution was also reported, however, comparison of bare gold nanoparticles and PEGylated gold nanoparticles with equal particle size is not sufficient. OBJECTIVE: We prepared bare gold nanoparticles and PEGylated gold nanoparticles with diameters of 20-30-nm or 50-nm to avoid the influence of particle diameter, and studied their biodistribution in the mouse. METHODS: Gold concentrations in brain, heart, lungs, liver, stomach, pancreas, spleen, kidneys, blood, urine, and feces were measured at 0.5, 1, 2, 3, 6, 12, 18, 24, and 48 h after administration of gold nanoparticles using inductively coupled plasma atomic emission spectrometry. RESULTS: At 48 h after intravenous administration, accumulation in the liver and spleen was significantly reduced by PEGylation, and the gold amounts of PEGylated gold nanoparticles with diameters of 20-30 nm and 50-nm in the brain were 3.6 times and 2.7 times higher than those of bare gold nanoparticles, respectively. CONCLUSIONS: These results indicated that the usefulness of PEGylated gold nanoparticles with small particle size for a drug carrier.
Authors: Amber Gonda; Nanxia Zhao; Jay V Shah; Hannah R Calvelli; Harini Kantamneni; Nicola L Francis; Vidya Ganapathy Journal: Med One Date: 2019-09-30